Alzinova AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.alzinova.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer DiseaseDementia AlzheimersDementia, Mild
- Interventions
- Other: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Alzinova AB
- Target Recruit Count
- 33
- Registration Number
- NCT05328115
- Locations
- 🇫🇮
Clinical Research Services Turku -CRST Oy, Turku, Finland
News
Alzinova's ALZ-101 Vaccine Advances to Phase 2 Trial Following Successful Drug Substance Production
Alzinova AB has successfully released the drug substance for its ALZ-101 vaccine candidate, enabling final drug product manufacturing for an upcoming Phase 2 clinical trial in early Alzheimer's disease scheduled to begin in the second half of 2025.